The ASX 200 is home to some high quality companies that have significant long term potential.
Two that have recently been rated as buys are listed below. Here's why these ASX 200 shares could be in the buy zone:
CSL Limited (ASX: CSL)
The first ASX 200 share to look at is biotherapeutics giant CSL. Its CSL Behring and Seqirus businesses have a portfolio of life-saving and lucrative therapies and vaccines which are generating billions of dollars in sales each year.
But management never rests on its laurels. Each year it invests in the region of 10% to 11% of its sales back into research and development (R&D) activities. This means that CSL will be investing around US$1 billion into its R&D this year. This ensures that the company has pipeline of therapies under development that could drive its future growth.
In addition, CSL is in the process of acquiring Vifor Pharma for ~$17 billion. Management notes that the deal expands its leadership across an attractive portfolio focused on renal disease and iron deficiency. It also highlights that Vifor has a high quality pipeline and complements CSL's existing therapeutic focus areas including Haematology, Thrombosis, Cardiovascular, and Transplant.
Citi is bullish on CSL and has a buy rating and $340.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 share to look at is ResMed. It is a leading sleep treatment-focused medical device company with a portfolio of products improving the lives of sufferers of conditions such as sleep apnoea.
ResMed has been growing at a solid rate for well over a decade and shows no signs of stopping any time soon. This is due to its leadership position in a market which continues to grow as education around sleep disorders improves.
In addition, with one of its key competitors continuing to work its way through a massive product recall, ResMed looks well-placed to win market share. This, combined with its patient-centric, connected-care digital platform, bodes well for its growth in the coming years.
Morgans is a big fan of the company and has an add rating and $40.46 price target on its shares.
